about
Formulation of buprenorphine for sublingual use in neonatesPractical considerations for the clinical use of buprenorphine.Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers.Buprenorphine: a (relatively) new treatment for opioid dependence.Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine.Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humansDrug testing in oral fluid.Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.Pharmacologic treatments for opioid dependence: detoxification and maintenance options.Effects of buprenorphine on responses to social stimuli in healthy adults.Effect of thienorphine on intestinal transit and isolated guinea-pig ileum contraction.Interpretation of oral fluid tests for drugs of abuse.Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans.The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.Design and evaluation of matrix-based controlled release tablets of diclofenac sodium and chondroitin sulphate.Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market.Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects.The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice.A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration.Opioid Use Disorder in Pregnancy.Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations.Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system.Buprenorphine in the treatment of opiate dependence.Recent development in therapeutics for breakthrough pain.Evaluation of analgesic effect and absorption of buprenorphine after buccal administration in cats with oral disease.Impact of the blood sampling site on time-concentration drug profiles following intravenous or buccal drug administration.Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers.Case series of buprenorphine injectors in Kuala Lumpur, Malaysia.A case of heroin overdose reversed by sublingually administered buprenorphine/naloxone (Suboxone).The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine.Buprenorphine in Neonatal Abstinence Syndrome.Effects of buprenorphine on responses to emotional stimuli in individuals with a range of mood symptomatology.Rapid Identification of Buprenorphine in Patient Saliva.Perioperative management of a patient undergoing Clagett window closure stabilized on Suboxone® for chronic pain: a case report.Inhibition of glucuronidation and oxidative metabolism of buprenorphine using GRAS compounds or dietary constituents/supplements: in vitro proof of concept.Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.Development of biodegradable drug delivery system to treat addiction.Comparison of two formulations of buprenorphine in cats administered by the oral transmucosal route.Buprenorphine and pain treatment in pediatric patients: an update.
P2860
Q24596701-6204BFD9-5F9C-49C3-9E54-EAF55851D2AFQ33774853-C7FC3263-1623-4E9A-ADFD-EC3BB68CD47EQ34138291-6A85B0B2-8A37-4FBA-AFA5-EC589DB7629EQ34365302-4721D026-9C32-4A99-BA3F-68164C048229Q34787766-CB18AF5B-4F54-481C-9505-8468280F7584Q34979634-FB6D6454-1A0F-4766-8B93-2482AD00F971Q35053485-B030EB0B-D66C-42D3-9DEB-FD4D1BC89CEBQ35160035-2930B9C4-C93E-414E-89CF-D5F715EE1868Q35454866-D12082D1-CD3C-4025-8418-29E60939C1D3Q36414570-3532EEDA-D7BF-4DD0-807D-03901A6D60E6Q36699289-AB5B875D-FC5A-4B0A-8330-8591FA79CD38Q36748917-5B6EF5E5-680D-441A-AF3E-961915AD617EQ36874673-A10E5AA9-1AEE-4C67-8598-5F6331307191Q37180966-8048A357-EFAE-43CA-8761-901186ADACF4Q37360847-DCBD410B-B3B3-491C-A873-0D279A03862CQ37429615-89C72B2E-A946-4B94-9FF6-0DAC10626257Q37470350-303773B1-0841-4076-BCD9-99C9A562066DQ37579953-75B6AD74-F707-4F8C-A103-D85161E95DA4Q38634946-9674A75B-7C1E-4B4B-AF08-40FC4C17465BQ38661092-7F2D2BBA-18DD-49A3-A8DD-88E4A5F454A9Q39340617-E63F8470-EE56-44B9-8FB6-E989E182D756Q41669477-554DA592-680A-4DD6-ADFA-F1E28976DDADQ42237962-044F312E-4CA7-45FA-AE9D-F196718C2843Q42962930-F1086334-2A95-4921-84FB-F5F3AC9F4A4EQ43085276-63782681-9DA8-4FE3-B4BB-571158709090Q43561666-F1A565ED-3477-436B-8EC4-543A9E89F4BDQ43644262-2B56123D-1A0F-4B21-8F58-A2A48CDAA351Q44342476-9A8338DF-DB17-46E7-B5AA-738812CB177DQ46515339-AAA1FFB5-B7AC-4475-B5E1-9565547A5992Q46540071-A20FCEC2-145F-466F-8307-E57C8007B916Q47556854-9E3C718D-9E0B-41C1-9C7F-724AEE7C95CAQ47653755-CEAC7038-A829-4241-8265-FEA3AF06EF3DQ47657602-3DC048A4-E587-4EF7-8A97-FA4976562C01Q47759707-8BF8FF36-FF67-4466-8EED-DD0E0BA4EFF0Q47849102-CF2712A8-F465-434A-B68F-05AD689C1CFAQ48177006-FC908A7E-FE03-47BC-8B60-9BF57F71A617Q51579656-AEEC109C-92BE-4EB4-BDCC-02727A0FFCCAQ52277158-2CD4F68B-0C01-493B-A750-993998924212Q53647394-D52DC0F0-A817-42AB-A300-0F7E66A1DC95Q55078240-CFE52B9C-E444-4C45-BE3E-021C2AE26B92
P2860
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Bioavailability of sublingual buprenorphine.
@ast
Bioavailability of sublingual buprenorphine.
@en
Bioavailability of sublingual buprenorphine.
@nl
type
label
Bioavailability of sublingual buprenorphine.
@ast
Bioavailability of sublingual buprenorphine.
@en
Bioavailability of sublingual buprenorphine.
@nl
prefLabel
Bioavailability of sublingual buprenorphine.
@ast
Bioavailability of sublingual buprenorphine.
@en
Bioavailability of sublingual buprenorphine.
@nl
P2093
P2860
P1476
Bioavailability of sublingual buprenorphine.
@en
P2093
Everhart ET
Jacob P 3rd
Mendelson J
P2860
P356
10.1177/009127009703700106
P577
1997-01-01T00:00:00Z